Loading company…
MyOme uses whole-genome sequencing to provide inherited disease risk and pharmacogenomics reports.
MyOme Inc. analyzes clinical-grade whole-genome sequencing data to provide health risk and pharmacogenomics reports. Its analysis covers conditions including cardiac disease, diabetes, autoimmune conditions, cancer, rare diseases, and medication response. Founded in 2017, the company is based in Palo Alto, US, and is led by CEO Premal Shah, PhD. In June 2022, it raised USD 32 million in Series B funding at a USD 132 million post-money valuation.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in